UFCW Canada lifetime fundraising for Leukemia & Lymphoma Society of Canada tops $49 million thanks to $1.86 million campaign in 2021-2022
June 17, 2022 13:22 ET
|
UFCW Canada
TORONTO, June 17, 2022 (GLOBE NEWSWIRE) -- Another year of pandemic restrictions presented unique challenges for UFCW Canada’s fundraising efforts on behalf of the Leukemia & Lymphoma Society...
Protein Kinase Inhibitors in Oncology Analysis Service 2022: Must have Handbook for Any Business Developer, BI/CI Operative or Clinical Developer
June 15, 2022 07:58 ET
|
Research and Markets
Dublin, June 15, 2022 (GLOBE NEWSWIRE) -- The "Protein Kinase Inhibitors in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.Protein Kinase Inhibitors in...
Global Bruton Tyrosine Kinase (BTK) Inhibitors Market Size to Expand Significantly USD 4476.99 Million By 2030
May 11, 2022 16:00 ET
|
Fior Markets
Newark, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- As per the report published by MRInsights.biz, the global Bruton tyrosine kinase (BTK) inhibitors market is expected to grow from USD 2,695.35 million in...
Oncolyze Announces FDA Orphan Drug Designation for OM-301 for the Treatment of Acute Myeloid Leukemia
January 05, 2022 09:00 ET
|
Oncolyze Inc
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncolyze, Inc, a biotech developing a disruptive technology for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA)...
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
December 16, 2021 07:00 ET
|
IN8bio, Inc
The ongoing Phase 1 trial of INB-100 is the first and most clinically advanced program administering large systemic doses of allogeneic gamma-delta T cells to patients 3 patients have been treated to...
Global Acute Lymphoblastic Leukemia Treatment Market Report 2021-2026: Opportunities with Limited Players in the Market & Increasing Investment in R&D of Different Leukemia Treatments
December 14, 2021 05:48 ET
|
Research and Markets
Dublin, Dec. 14, 2021 (GLOBE NEWSWIRE) -- The "Global Acute Lymphoblastic Leukemia Treatment Market (2021-2026) by Type, Types of Cell, Therapy, Geography, Competitive Analysis and the Impact of...
Tyrokinse Kinase Inhibitors in the Global Oncology Market 2021: Market Leaders by Indication and Product
November 05, 2021 05:58 ET
|
Research and Markets
Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Oncology Markets for Tyrokinse Kinase Inhibitors" report has been added to ResearchAndMarkets.com's offering. Traditional cancer therapy has focused...
Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application Protecting Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents
October 04, 2021 07:00 ET
|
Starton Therapeutics, Inc.
PARAMUS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., a clinical stage biotechnology company transforming standard of care therapies with proprietary dermal technologies, today...
AB Science a reçu l’approbation de l’autorité de santé canadienne pour initier une étude de Phase I/II avec sa molécule AB8939 dans le traitement de la leucémie myéloïde aiguë (LMA)
September 22, 2021 12:09 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE L’AUTORITE DE SANTÉ CANADIENNE POUR INITIER UNE ÉTUDE DE PHASE I/II AVEC SA MOLÉCULE AB8939 DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË...
AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
September 22, 2021 12:09 ET
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES HEALTH CANADA APPROVAL LETTER TO COMMENCE PHASE I/II TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AB8939 IS A NEW GENERATION SYNTHETIC...